BioAmicus Complete for infants with colic, reflux, constipation, or loose stools (0–24 months)
Official title: Evaluation of the Efficacy and Safety of the Multistrain Probiotic "BioAmicus Complete" in Improving Gastrointestinal Symptoms in Children Aged 0-24 Months: A Randomized, Open-Label, Parallel-Group, Controlled Trial
Run by Haiphong University of Medicine and Pharmacy · NCT07148583 · Data updated 2026-11-12
This study will see if the multistrain probiotic BioAmicus Complete can help reduce caregiver‑reported tummy symptoms in infants aged 0–24 months.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 0 Days to 24 Months |
| Sex | All |
| Enrollment | 110 (estimated) |
| Sponsor | Haiphong University of Medicine and Pharmacy Academic / other |
| Locations | 1 site (Haiphong, Hai Phong) |
| Status | Recruiting |
| Started | September 5, 2025 |
| Main results expected | April 30, 2026 |
| Study ends | May 30, 2026 |
| Registry record updated | January 29, 2026 |
| Trial ID | NCT07148583 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are infants aged 0–24 months with clinician‑assessed functional GI symptoms whose caregivers can provide consent, complete questionnaires/diaries, collect stool samples as requested, and avoid other probiotic products during the study.
✕Probably not a fit
Infants with major congenital gastrointestinal anomalies, chronic GI diseases requiring ongoing prescription therapy, known immunodeficiency or current immunosuppression, or clinically unstable severe illness are excluded and unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study randomizes infants with clinician‑assessed functional gastrointestinal symptoms to receive BioAmicus Complete or usual care and follows them over the study period to measure change in symptoms. The primary outcome is the change in Infant Gastrointestinal Symptom Questionnaire (IGSQ) total score from baseline to end of study. Secondary outcomes include symptom domains (colic/regurgitation, stool frequency and consistency), caregiver quality of life, growth, health care use and antibiotic exposure, and safety monitoring for adverse events. Stool samples will be collected for exploratory analysis of microbiome composition and diversity to explore biological changes associated with symptom changes.
Why it matters
Potential benefit: If successful, this could offer a safe, easy‑to‑use probiotic option to reduce infant gastrointestinal symptoms and lower caregiver burden.
How similar studies have gone: Some single‑strain probiotics have shown benefits for specific infant symptoms like colic or regurgitation in prior trials, but results are mixed and multistrain formulations such as BioAmicus Complete have not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 0-24 months at enrollment. * Infant has clinician-assessed functional gastrointestinal symptoms (e.g., colic/irritability, regurgitation, constipation, loose stools), judged suitable for study participation. * Parent or legal guardian provides written informed consent and agrees to comply with study procedures (questionnaires/diaries and sample collection, if applicable). * Caregivers agree to avoid other probiotic products during the study period, except as directed by the study team. Exclusion Criteria: * Major congenital gastrointestinal anomalies or known chronic gastrointestinal diseases requiring ongoing prescription therapy (e.g., Hirschsprung disease, inflammatory bowel disease, short-bowel syndrome). * Clinically unstable condition or severe/critical illness that could interfere with participation or safety in the opinion of the investigator. * Known or suspected primary or secondary immunodeficiency, or current immunosuppressive therapy. * History of severe allergy or hypersensitivity to components of the investigational product. * Recent use of systemic antibiotics within 14 days prior to baseline, or use of probiotic supplements within 14 days prior to baseline (per protocol). * Participation in another interventional clinical trial within 30 days prior to enrollment or during the study. * Any condition that, in the investigator's judgment, would make the participant unsuitable for the study or confound outcome assessments.
Where it's running
-
Clinical Trial and Bioequivalence Center
Haiphong, Hai Phong, Vietnam Recruiting
Study contacts
- Study coordinator: Nguyen Thi Thu Phuong, MD, PhD
- Email: nttphuong@hpmu.edu.vn
- Phone: +84936685007
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Probiotic in IBS-D and functional diarrhea (three-month test)
A probiotic capsule is being tested to see if it can improve symptoms and quality of life for adults with diarrhea-predominant IBS or functional diarrhea compared with a placebo.
-
Effect of Periodontal Therapy on Gut Microbes and Inflammation in People with Inflammatory Bowel Disease
This study tests whether treating gum disease in people with inflammatory bowel disease can influence the gut microbiome and markers of systemic inflammation.
-
Probiotics for infant colic: does daily L. reuteri help crying time?
This study tests whether giving healthy infants with Rome IV–defined colic a daily probiotic (L. reuteri) reduces crying and fussing more quickly than a placebo.
-
Core-based movement plus nutrition for stress and metabolic health in overweight women with functional constipation
This study tests whether an 8-week core-based exercise program plus nutritional counseling improves stress, cortisol, and lipid levels in overweight women with functional constipation.
-
Metabolic and Functional Study of γδ T Cells in Critically Ill Patients
Researchers will look at how γδ T cells behave in severely ill patients, including those with sepsis, to see how their metabolism and function change.
-
Pulse-focused nutrition for school-age children
This 6-week program tests whether a pulse-based diet (1.5 cups per week) improves gut health and metabolic markers in kids aged 6–13 who receive either pulses with education or pulses plus education and procurement support.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.